Cordex Pharma, Inc. (Cordex) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine 5′-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders.
Cordex is developing a portfolio of therapeutic and diagnostic products, two of which are in advanced stages of clinical studies. Cordex is now preparing for a pivotal Phase 3 clinical trial with ATPace as an anti-arrhythmic drug for the treatment of paroxysmal supraventricular tachycardia and a proof-of-concept Phase 2 clinical trial with CDP-1050 for the treatment of heart failure. In addition, Cordex has a preclinical drug discovery program aimed at a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease and chronic cough.